Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Raptiva Withdrawal Shows Comparative Safety Focus From New, Decisive FDA

Executive Summary

Market withdrawal of Genentech's psoriasis drug Raptiva (efalizumab) shows FDA under new leadership acting decisively on drug safety - especially in cases where comparable treatment alternatives exist

You may also be interested in...



Biogen Idec Suggests PML Risk Manageable For Tecfidera, After Reporting First Case

Biogen Idec noted that 100,000 patients have been treated with the drug since launch and emphasized that the only reported PML case occurred in a patient on long-term treatment despite having a known risk factor.

New Orals, Better Topicals Top Psoriasis Wish List

Biologics for psoriasis leapfrogged existing treatments in the last decade, greatly improving the standard of care. Although those may still see incremental improvements, the real changes for patient care may come with the introduction of new oral and topical treatments. START-UP profiles four emerging companies that are tackling this challenge: Avexxin, Cellceutix, Creabilis, and Convoy Therapeutics.

FDA/EMA/Industry Action On PML Heralds New Foray Into Collaboration

FDA, the European Medicines Agency and the pharmaceutical industry have embarked on a new cooperative effort to develop solutions to drug-related progressive multifocal leukoencephalopathy – a collaboration that could be a springboard for better disease/drug-specific cooperation.

Related Content

Topics

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel